» Articles » PMID: 29475397

Fatty Acid Synthase is Required for Profibrotic TGF-β Signaling

Overview
Journal FASEB J
Specialties Biology
Physiology
Date 2018 Feb 25
PMID 29475397
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Evidence is provided that the fibroproliferative actions of TGF-β are dependent on a metabolic adaptation that sustains pathologic growth. Specifically, profibrotic TGF-β signaling is shown to require fatty acid synthase (FASN), an essential anabolic enzyme responsible for the de novo synthesis of fatty acids. With the use of pharmacologic and genetic approaches, we show that TGF-β-stimulated FASN expression is independent of Smad2/3 and is mediated via mammalian target of rapamycin complex 1. In the absence of FASN activity or protein, TGF-β-driven fibrogenic processes are reduced with no apparent toxicity. Furthermore, as increased FASN expression was also observed to correlate with the degree of lung fibrosis in bleomycin-treated mice, inhibition of FASN was examined in a murine-treatment model of pulmonary fibrosis. Remarkably, inhibition of FASN not only decreased expression of profibrotic targets, but lung function was also stabilized/improved, as assessed by peripheral blood oxygenation.-Jung, M.-Y., Kang, J.-H., Hernandez, D. M., Yin, X., Andrianifahanana, M., Wang, Y., Gonzalez-Guerrico, A., Limper, A. H., Lupu, R., Leof, E. B. Fatty acid synthase is required for profibrotic TGF-β signaling.

Citing Articles

Broadening horizons: molecular mechanisms and disease implications of endothelial-to-mesenchymal transition.

Qian C, Dong G, Yang C, Zheng W, Zhong C, Shen Q Cell Commun Signal. 2025; 23(1):16.

PMID: 39789529 PMC: 11720945. DOI: 10.1186/s12964-025-02028-y.


Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).

Do A, Zahrawi F, Mehal W Nat Rev Drug Discov. 2024; 24(3):171-189.

PMID: 39609545 DOI: 10.1038/s41573-024-01084-2.


Metabolic profiling of idiopathic pulmonary fibrosis in a mouse model: implications for pathogenesis and biomarker discovery.

Zhang Y, Jia X, Xu W, Ding X, Wang X, Chi X Front Med (Lausanne). 2024; 11:1410051.

PMID: 39175820 PMC: 11340507. DOI: 10.3389/fmed.2024.1410051.


Fibrotic pathways and fibroblast-like synoviocyte phenotypes in osteoarthritis.

Damerau A, Rosenow E, Alkhoury D, Buttgereit F, Gaber T Front Immunol. 2024; 15:1385006.

PMID: 38895122 PMC: 11183113. DOI: 10.3389/fimmu.2024.1385006.


p63 controls metabolic activation of hepatic stellate cells and fibrosis via an HER2-ACC1 pathway.

Fondevila M, Novoa E, Gonzalez-Rellan M, Fernandez U, Heras V, Porteiro B Cell Rep Med. 2024; 5(2):101401.

PMID: 38340725 PMC: 10897550. DOI: 10.1016/j.xcrm.2024.101401.


References
1.
Kuhajda F . Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition. 2000; 16(3):202-8. DOI: 10.1016/s0899-9007(99)00266-x. View

2.
Swinnen J, Ulrix W, Heyns W, Verhoeven G . Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc Natl Acad Sci U S A. 1997; 94(24):12975-80. PMC: 24248. DOI: 10.1073/pnas.94.24.12975. View

3.
Svensson R, Shaw R . Lipid Synthesis Is a Metabolic Liability of Non-Small Cell Lung Cancer. Cold Spring Harb Symp Quant Biol. 2017; 81:93-103. DOI: 10.1101/sqb.2016.81.030874. View

4.
Chaudhary N, Schnapp A, Park J . Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006; 173(7):769-76. DOI: 10.1164/rccm.200505-717OC. View

5.
Rahimi R, Andrianifahanana M, Wilkes M, Edens M, Kottom T, Blenis J . Distinct roles for mammalian target of rapamycin complexes in the fibroblast response to transforming growth factor-beta. Cancer Res. 2009; 69(1):84-93. PMC: 2656374. DOI: 10.1158/0008-5472.CAN-08-2146. View